Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 6/20 | 0.64 |
| ▸ | NT5E | P21589 | 1/20 | 0.64 |
| ▸ | GSK3A | P49840 | 2/20 | 0.61 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.61 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.61 |
| ▸ | TGM2 | P21980 | 1/20 | 0.60 |
| ▸ | PNP | P00491 | 1/20 | 0.58 |
| ▸ | KRAS | P01116 | 9/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6826563 | 0.89 | HINT1 (0.68) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL7098413 | 0.88 | HINT1 (0.67) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL6239924 | 0.88 | HINT1 (0.73) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL2533738 | 0.87 | HINT1 (0.69) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL6889003 | 0.86 | HINT1 (0.70) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL2335177 | 0.86 | HINT1 (0.69) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL1138984 | 0.86 | HINT1 (0.75) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL6245258 | 0.85 | HINT1 (0.69) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL5501200 | 0.85 | HINT1 (0.69) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL9116032 | 0.85 | HINT1 (0.66) | HINT1NT5EGSK3ARPS6KA3MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2872147-A2 | CHIRAL CONTROL | Wave Life Sciences Pte. Ltd. (SG) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014012081-A2 | CHIRAL CONTROL | ONTORII, INC. (US) | 2014-01-16 | — | — | WO | disclosed |
| US-7569685-B2 | Artificial RNAóS modified at the 2ó-hydroxyl group | JAPAN SCIENCCE AND TECHNOLOGY AGENCY (JP) | 2009-08-04 | — | — | US | disclosed |
| US-20080021206-A1 | Novel Artificial Rnaos Modified At The 2o-Hydroxyl Group | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2008-01-24 | — | — | US | disclosed |
| EP-1726597-A1 | NOVEL ARTIFICIAL RNAóS MODIFIED AT THE 2ó-HYDROXYL GROUP | Japan Science and Technology Agency (JP) | 2006-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021206-A1 | Novel Artificial Rnaos Modified At The 2o-Hydroxyl Group | FBL, NSUN2, METTL16 | HINT1 1075/4885NT5E 1067/4885GSK3A 3674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.